Study suggests critical connection between residual FLT3-ITD mutations in remission and post-transplant outcomes in AML

2024-05-09 02:54:51

A groundbreaking research study,¹ sequencing of DNA samples from the Pre-MEASURE study² strongly indicates that detection ofresidual internal tandem duplication (ITD) mutations of FLT3 in the blood of adult individuals with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes following allogeneic hematopoietic cell transplantation (HCT).

This follow-up study tested for measurable residual disease (MRD) on the DNA of 537 individuals withLMA with FLT3 -ITD mutation from the Pre-MEASURE study using the RUO kitof tests FLT3 ITD MRD from Invivoscribe and bioinformatics software. Their findings highlight the likely importance ofFLT3 -Residual ITD at first CR in predicting relapse and post-transplant mortality.

An important finding of this research study was that individuals with AML with FLT3 -Residual ITD detected before allogeneic HCT tended to have an elevated risk of relapse and post-transplant mortality, with a dose-dependent correlation within this study population.

Hourigan, director of the Virginia Tech FBRI Cancer Research Center in Washington, D.C. and the study’s principal investigator, noted, “This research highlights the value of pre-transplant testing to FLT3 -Residual ITD in adults with AML. The association of MRD test results with post-transplant outcomes opens up the potential to refine treatment strategies to improve survival.”

Going forward, the study calls for more research to explore alternative approaches for high-risk populations who may not benefit from current standard care protocols.

Jeff Miller, CEO/CSO of Invivoscribe, commented: “We are excited to observe the remarkable association of clinical outcomes that have been so clearly delineated using our testing and software-only research. This research study increases our understanding of AML monitoring and treatment. ”

About Invivoscribe

Invivoscribe is a global, vertically integrated biotechnology company dedicated to improving lives with precision diagnostics.^®). For nearly thirty years, Invivoscribe has improved the quality of healthcare around the world by offering high-quality reagents, tests, bioinformatics tools and standardized services to advance the field of precision medicine. Invivoscribe has a successful track record of partnering with global pharmaceutical companies interested in developing and commercializing companion diagnostics and offers expertise in regulatory and laboratory services. By providing distributable kits as well as clinical trial services through its globally located clinical laboratory subsidiaries (LabPMM), Invivoscribe is an ideal partner in diagnostic and clinical trial development, regulatory submission and commercialization. For additional information, visit www.invivoscribe.com or contact us via email [email protected] and follow us on Linked In.

1. Measurable ResidualFLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia, Dillonet al JAMA Oncology, published online May 2, 2024.

2. DNA Sequencing to Detect Residual Disease in Adults with Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant, Dillon et al JAMA 2023; 329 (9): 745-755

The original language text of this announcement is the official authorized version. Translations are provided as a facility only and must refer to the text in the original language, which is the only version of the text that has legal effect.

View original version on businesswire.com:

Contact:

[email protected]

Source: BUSINESS WIRE

1715226213
#Study #suggests #critical #connection #residual #FLT3ITD #mutations #remission #posttransplant #outcomes #AML